Multiple mechanisms and recurrent somatic mutations have been identified that contribute to melanoma resistance, including alterations in genes such as BRAF, NRAS, and PTEN, as well as the activation of cell signaling pathways that promote cell survival and proliferation, such as the MAPK and PI3K/AKT pathways [23,24]. This evidence concerns the gene PTEN and melanoma.